Multivariate analysis of factors on DFS (from day 85)
| Variable . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| WBC at diagnosis, × 109/L | 1.005 (0.993-1.017) | .4358 |
| Age, y (as continuous variable) | 1.003 (0.971-1.037) | .8414 |
| Sex (female vs male) | 2.501 (1.010-6.193) | .0476 |
| BCR-ABL reduction day 85, < 10−3 vs ≥ 10−3 | 0.336 (0.126-0.895) | .0291 |
| Immunophenotypic reduction day 85, < 10−2 vs ≥ 10−2 | 0.411 (0.120-1.405) | .1562 |
| BCR-ABL type, p190 vs p210 | 0.446 (0.181-1.100) | .0797 |
| BCR-ABL type, p190/p210 vs p210 | 0.518 (0.129-2.070) | .3517 |
| Other comparisons | ||
| BCR-ABL type: p190/p210 vs p190 | 1.159 (0.293-4.592) | .8335 |
| Variable . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| WBC at diagnosis, × 109/L | 1.005 (0.993-1.017) | .4358 |
| Age, y (as continuous variable) | 1.003 (0.971-1.037) | .8414 |
| Sex (female vs male) | 2.501 (1.010-6.193) | .0476 |
| BCR-ABL reduction day 85, < 10−3 vs ≥ 10−3 | 0.336 (0.126-0.895) | .0291 |
| Immunophenotypic reduction day 85, < 10−2 vs ≥ 10−2 | 0.411 (0.120-1.405) | .1562 |
| BCR-ABL type, p190 vs p210 | 0.446 (0.181-1.100) | .0797 |
| BCR-ABL type, p190/p210 vs p210 | 0.518 (0.129-2.070) | .3517 |
| Other comparisons | ||
| BCR-ABL type: p190/p210 vs p190 | 1.159 (0.293-4.592) | .8335 |